Skip to Content

Generic Omnipred Availability

Omnipred is a brand name of prednisolone ophthalmic, approved by the FDA in the following formulation(s):

OMNIPRED (prednisolone acetate - suspension/drops;ophthalmic)

  • Manufacturer: NOVARTIS PHARMS CORP
    Approved Prior to Jan 1, 1982
    Strength(s): [AB]

Has a generic version of Omnipred been approved?

An Authorized Generic version of Omnipred has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance, and unlike a generic, the Authorized Generic has exactly the same inactive ingredients.

List of authorized generic versions:

  • Prednisolone Acetate OPHTHALMIC SUSPENSION/ DROPS 10 mg/mL
    A-S Medication Solutions
    NDC Code: 500900559
  • Prednisolone Acetate OPHTHALMIC SUSPENSION/ DROPS 10 mg/mL
    A-S Medication Solutions
    NDC Code: 500900561
  • Prednisolone Acetate OPHTHALMIC SUSPENSION 10 mg/mL
    Physicians Total Care, Inc.
    NDC Code: 548684293
  • Prednisolone Acetate OPHTHALMIC SUSPENSION/ DROPS 10 mg/mL
    Sandoz Inc.
    NDC Code: 613140637

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Omnipred. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.